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Problem: The immune cellular composition of amniotic fluid is poorly understood. 
Herein, we determined: 1) the immunophenotype of amniotic fluid immune cells dur-
ing the second and third trimester in the absence of intra-amniotic infection/inflam-
mation; 2) whether amniotic fluid T cells and ILCs display different phenotypical 
characteristics to that of peripheral cells; and 3) whether the amniotic fluid immune 
cells are altered in women with intra-amniotic infection/inflammation.
Method of Study:	Amniotic	fluid	samples	(n	=	57)	were	collected	from	15	to	40	weeks	
of gestation in women without intra- amniotic infection/inflammation. Samples from 
women	 with	 intra-	amniotic	 infection/inflammation	 were	 also	 included	 (n	=	9).	
Peripheral	blood	mononuclear	cells	from	healthy	adults	were	used	as	controls	(n	=	3).	
Immunophenotyping was performed using flow cytometry.












Conclusion: The amniotic fluid harbors a diverse immune cellular composition during 
normal and complicated pregnancies.
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1  | INTRODUC TION
Amniotic	 fluid	 is	 the	 protective	 liquid	 that	 surrounds	 the	 fetus	
throughout gestation and, therefore, is essential for fetal devel-
opment and maturation.1 Besides containing nutrients and other 
factors	 required	 for	 fetal	 growth,	 the	 amniotic	 fluid	 provides	me-
chanical cushioning and represents an immunological barrier against 
invading pathogens.1,2 The amniotic fluid is used as a diagnostic tool 
for assessing fetal well- being,3-7 lung maturity,8-11	 karyotype,12-15 
and intra- amniotic infection and/or inflammation.16-74 During early 
development,	the	amniotic	fluid	is	an	extension	of	the	fetal	extracel-
lular	matrix.75	As	the	placenta	and	fetal	vessels	emerge,	water	and	
solutes from the maternal plasma diffuse into the amniotic fluid.76 
By	8	weeks	of	gestation,	the	urethra	is	formed	and	the	fetal	kidneys	
start producing urine.77 Shortly after, fetal swallowing begins;75 
however, these processes do not contribute to the amniotic fluid vol-
ume until the second half of pregnancy.77	After	25	weeks	of	gesta-
tion,	the	fetal	skin	is	fully	keratinized78 and the amniotic fluid volume 
is determined by factors comprising the amniotic fluid circulation 
(fetal	 urine,	 respiratory	 system,	 gastrointestinal	 system,	 umbilical	
cord, and placenta).75,77-80
The amniotic fluid contains soluble and cellular components.77 
The soluble components include carbohydrates, proteins, peptides, 
lipids, lactate, pyruvate, electrolytes, enzymes, and hormones, among 
others,81-99 many of which act as the first line of defense against 
pathogens invading the amniotic cavity.100-106 The cellular compo-
nents of the amniotic fluid include different cell types derived from 
exfoliating	surfaces	of	the	developing	fetus,	including	the	skin,	respi-
ratory system, urinary tract, and gastrointestinal tract as well as stem 
cells.107-115 Some cytological studies have shown that, in the absence 
of infection, the amniotic fluid also includes a low number of innate 
immune cells including macrophages,110,111,116-118 neutrophils,23,69 
and the recently described innate lymphoid cells or ILCs.119 Yet, the 
number of macrophages and/or ILCs is increased in pathological con-
ditions	 in	which	 fetal	organs	are	exposed	 to	 the	amniotic	 fluid	 (eg,	
neural tube defects118,120-125 and gastroschisis118,126-128). The number 
of	amniotic	fluid	neutrophils,	on	the	other	hand,	is	a	useful	marker	for	
intra- amniotic inflammation.23,27,67-69,129-132 However, in the absence 
of infection and/or inflammation or birth defects, the immune cellular 
composition of the amniotic fluid is still poorly understood.
The	 aims	 of	 this	 study	were	 (i)	 to	 determine	 the	 immunophe-
notype of amniotic fluid immune cells during the second and third 
trimester,	 (ii)	to	 investigate	whether	amniotic	fluid	T	cells	and	ILCs	
display different phenotypical characteristics from that of peripheral 
cells;	and	(iii)	to	evaluate	whether	the	amniotic	fluid	immune	cells	are	
altered in women with intra- amniotic infection/inflammation.
2  | MATERIAL S AND METHODS
2.1 | Study population
This was a cross- sectional study of patients who underwent transab-
dominal amniocentesis due to clinical indications or amniocentesis 
during a cesarean delivery. Patients were enrolled at Hutzel Women’s 
Hospital of the Detroit Medical Center. The first group of patients 
(n	=	57,	 absence	 of	 intra-	amniotic	 infection/inflammation)	 was	 se-
lected	based	on	the	following	exclusion	criteria:	a	positive	amniotic	
fluid culture,20,39,54	a	white	blood	cell	 (WBC)	count	>50	cells/mm,23 
a glucose concentration <14 mg/dL,22	 an	 amniotic	 fluid	 interleukin	
(IL)-6	concentration	>2.6	ng/mL,39 a positive Gram stain,17 and/or a 
bacterial live/dead staining,68 and samples from women with an intra-
uterine	fetal	demise	and/or	birth	defects.	A	second	group	of	patients	
with	intra-	amniotic	infection/inflammation	was	also	included	(n	=	9).	
Intra- amniotic infection/inflammation was defined as the presence of 
microbial	 invasion	of	the	amniotic	cavity	(MIAC)	with	intra-	amniotic	




All	 patients	 provided	 written	 informed	 consent	 to	 donate	 ad-
ditional amniotic fluid for research purposes, according to proto-
cols approved by the Institutional Review Boards of the Detroit 
Medical	 Center	 (Detroit,	 MI,	 USA),	 Wayne	 State	 University	 and	
the Perinatology Research Branch, an intramural program of the 
Eunice Kennedy Shriver National Institute of Child Health and Human 




antiseptic conditions using a 22- gauge needle monitored by ultra-
sound.	 Amniotic	 fluid	 was	 also	 retrieved	 by	 amniocentesis	 during	
cesarean	deliveries	under	antiseptic	conditions.	Amniotic	fluid	sam-
ples were transported to the clinical laboratory in a capped sterile 
syringe and were cultured for aerobic and anaerobic bacteria as well 
as for genital Mycoplasmas.20,23,39,54 Shortly after collection, a WBC 
count in amniotic fluid samples was determined using a hemocytom-
eter chamber, according to methods previously described.23 Glucose 
concentration22 was also determined and a Gram stain17 was per-
formed in amniotic fluid samples. Cultures, WBC counts, glucose 
concentrations, and Gram stains were not performed in amniotic 
fluid samples collected during cesarean section, as these samples 
were collected for research purposes only. However, both IL- 6 con-
centration39	and	the	presence	of	bacteria	(bacterial	live/dead	stain-
ing68) were assessed in all of the amniotic fluid samples.
2.3 | Determination of interleukin- 6 in the 
amniotic fluid
IL- 6 concentration in the amniotic fluid was determined using a sensi-
tive and specific enzyme immunoassay obtained from R&D Systems 
(Minneapolis,	MN,	USA).	 IL-	6	concentration	was	determined	by	in-
terpolation from the standard curves. The inter- and intra- assay co-
efficients of variation for IL- 6 were 8.7% and 4.6%, respectively. The 
detection limit of the IL- 6 assay was 0.09 pg/mL.
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incubated	 for	 15	min	 at	 room	 temperature	 in	 the	 dark.	 Next,	 the	
cells were centrifuged at 10 000 × g for 5 min and the supernatant 
was discarded. The cell pellet was then re- suspended in 5 μL of 1× 
PBS, and a slide smear was prepared and air- dried. Lastly, the slide 
was gently rinsed with 1× PBS and mounted with ProLong Diamond 
Antifade	 Mountant	 with	 4′,6-	diamidino-	2-	phenylindole	 or	 DAPI	
(Life	 Technologies).	 The	 presence	 of	 bacteria	was	 evaluated	 using	
an Olympus BX 60 fluorescence microscope with an Olympus DP71 
camera	and	DP	Controller	Software	(Olympus	Corporation,	Tokyo,	
Japan).
2.5 | Isolation of peripheral blood mononuclear cells
Peripheral	blood	samples	were	collected	by	venipuncture	into	EDTA-	







Germany) to remove most of the epithelial cells and centrifuged at 
200 × g for 5 minutes at room temperature. The resulting amniotic 
fluid	 leukocyte	pellet	or	PBMCs	were	re-	suspended	in	1	mL	of	1×	
PBS	 and	 stained	with	 the	BD	Horizon	 Fixable	Viability	 Stain	 510	
dye	(BD	Biosciences,	San	Jose,	CA,	USA),	prior	to	incubation	with	
extracellular	monoclonal	antibodies	 (Table	S1).	Cells	were	washed	
in 1× PBS and incubated with 20 μL	of	human	FcR	blocking	reagent	
(Miltenyi	Biotec,	 San	Diego,	CA,	USA)	 in	80	μL	of	BD	FACS	 stain	
buffer	(Cat#554656;	BD	Biosciences)	for	10	minutes	at	4°C.	Next,	
cells	 were	 incubated	 with	 extracellular	 fluorochrome-	conjugated	
anti-	human	monoclonal	antibodies	for	30	minutes	at	4°C	in	the	dark	
(Table	S1).	Following	extracellular	staining,	cells	were	fixed	and	per-
meabilized	 using	 the	 FoxP3	 transcription	 factor	 fixation/permea-
bilization	 solution	 (Cat#00-	5523-	00;	 eBioscience,	 San	Diego,	CA,	
USA).	 Following	 fixation	 and	permeabilization,	 cells	were	washed	
with	1×	FoxP3	permeabilization	buffer	(eBioscience),	re-	suspended	
in 50 μl of the same buffer, and stained with intracellular antibodies 
for	30	minutes	at	4°C	in	the	dark	(Table	S1).	Isotope	controls	were	




performed	 and	 the	 figures	were	 generated	 using	 the	 FlowJo	 v10	
software	 (FlowJo,	 Ashland,	 OR,	 USA).	 The	 absolute	 number	 of	
cells was determined using CountBright absolute counting beads 
(Molecular	Probes,	Eugene,	OR,	USA).
2.7 | Imaging flow cytometry of amniotic 
fluid leukocytes
Amniotic	 fluid	 samples	 (1-	10	mL;	 n	=	5)	 were	 passed	 through	 a	
sterile 15 μm filter to remove most of the epithelial cells and cen-
trifuged at 200 × g for 5 minutes at room temperature. The cell 
pellet	(mostly	leukocytes)	was	washed	with	1×	PBS,	re-	suspended	
in 80 μL	of	BD	FACS	stain	buffer	containing	20	μL of human FcR 
blocking	 reagent	 (Miltenyi	 Biotec),	 and	 incubated	 for	 10	min	 at	
4°C.	Next,	the	amniotic	fluid	leukocytes	were	stained	separately	
with	 the	 following	 two	 panels	 of	 extracellular	 fluorochrome-	
conjugated	anti-	human	antibodies	(BD	Biosciences)	for	30	minutes	
at	4°C	in	the	dark.	One	antibody	panel	included	CD45-	APC	(Clone	
HI30,	 Cat#555485),	 CD56-	PE	 (clone	 NCAM16.2,	 Cat#340363),	
CD14-	Alexa	Fluor®	 488	 (clone	MφP9,	Cat#562689)	 and	CD15-	
PE-	CF594	(clone	W6D3,	Cat#562372).	The	second	panel	included	
CD45-	APC	 (Clone	HI30),	 CD19-	 PE	 (clone	HIB19,	 Cat#555413),	
CD3-	Alexa	Fluor®	488	(clone	UCHT1,	Cat#557694),	and	CD127-	
PE-	CF594	 (clone	 HIL-	7R-	M21,	 Cat#562397).	 Following	 anti-
body	 staining,	 amniotic	 fluid	 leukocytes	 were	 fixed	 with	 4%	
paraformaldehyde	 (Electron	 Microscopy	 Sciences,	 Hatfield,	 PA,	
USA)	 for	 20	minutes	 at	 room	 temperature.	 Amniotic	 fluid	 cells	
were then rehydrated in 1× PBS and stained with 3 μmol/L	DAPI	
(Cat#D9542,	Sigma,	St.	Louis,	MO,	USA)	in	a	nuclear	permeabili-
zation	 buffer	 (Cat#00-	8333-	56,	 eBiosciences)	 for	 15	minutes	 at	
room temperature. Lastly, amniotic fluid cells were suspended 
in 50 μL	 of	 BD	 FACS	 stain	 buffer	 containing	 1	mg/mL	 EDTA	




MI,	 USA)	 (http://micr.med.wayne.edu/).	 Images	 were	 obtained	







lowed by Mann- Whitney U- tests were used for unpaired compari-
sons	among	study	groups.	Wilcoxon	signed	 rank	 tests	were	used	
for paired comparisons. t- SNE plots were generated using the 
FlowJo	v10	software.	A	P-	value	≤.05	was	considered	 statistically	
significant.
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3  | RESULTS
3.1 | Characteristics of the study population
A	total	of	66	amniotic	fluid	samples	from	women	who	underwent	
transabdominal amniocentesis before delivery or during a cesar-
ean delivery were included in this study. Demographic and clinical 
characteristics of the study population are displayed in Tables 1 




lected from women who underwent an amniocentesis for fetal 
karyotyping	and	delivered	a	term	neonate	(Table	2).	Amniotic	fluid	
samples	 obtained	 between	 20	 and	 36	weeks	 of	 gestation	 were	
collected from women who underwent an amniocentesis for the 
detection	of	 intra-	amniotic	 infection	and/or	 inflammation	 (nega-
tive)	 and	 delivered	 a	 preterm	 neonate	 (Table	2).	 Amniotic	 fluid	
samples	 obtained	 between	 36	 and	 40	weeks	 of	 gestation	 were	
mostly collected from women during the cesarean delivery proce-
dure	and	who	delivered	a	term	neonate	 (Table	2).	Amniotic	 fluid	
samples from women with intra- amniotic infection/inflammation 
were	collected	between	18	and	40	weeks	of	gestation	(Table	2).
3.2 | The immunophenotype of amniotic fluid 
leukocytes during the second and third trimester in the 
absence of intra- amniotic infection/inflammation
First,	we	 investigated	 the	 diversity	 of	 amniotic	 fluid	 leukocytes	
during the second and third trimester. Figure 1 shows representa-
tive t- SNE plots demonstrating that different immune cell popula-
tions are present throughout gestation. T cells and ILCs were the 
most	abundant	immune	cell	populations	between	15	and	20	weeks	
of	gestation	(Figure	1A).	Between	20	and	30	weeks	of	gestation,	B	
cells, monocytes, and neutrophils emerged, while T cells were still 
abundant	and	ILCs	were	drastically	reduced	(Figure	1B).	Between	
30	and	36	weeks	of	gestation,	neutrophils	and	monocytes	were	




3.3 | Lymphoid cells in the amniotic fluid during the 
second and third trimester in the absence of intra- 
amniotic infection/inflammation
Lymphoid	 cells	 were	 abundant	 between	 15	 and	 30	weeks	 of	 gesta-
tion	(Figure	1A,B);	therefore,	we	first	determined	which	lymphoid	sub-
set was more abundant during this period. The gating strategy used 
to	 identify	 lymphoid	cells	 in	 the	amniotic	 fluid	 is	shown	 in	Figure	2A.	
Briefly,	 total	 leukocytes	 were	 identified	 as	 CD45+		 cells	 within	 the	
singlets and viability gates. Identified lymphoid cells in the amniotic 
fluid	 included:	T	cells	 (CD45+CD15−CD14−CD19−CD3+	cells),	B	cells	
(CD45+CD15−CD14−CD3−CD19+	 cells),	 NK	 cells	 (CD45+CD15−







and	CD56−	 ILC	 subsets	were	 present	 in	 similar	 numbers	 (Figure	2C).	













TABLE  2 Clinical characteristics of the study population
Groups Number of samples
Gestational age at amniocen-
tesis (weeks; median [IQR])
IL- 6 concentration (ng/
mL; median [IQR])




15- 20 6 17.7	(16.4-	18.8) 0.3	(0.1-	0.8) 38.4	(38.4-	39.3)
20- 30 8 23.2	(21.6-	27.2) 0.5	(0.2-	0.9) 28.6	(24.5-	35.6)
30- 36 9 32.3	(31.4-	33.3) 0.3	(0.2-	0.4) 33.9	(32.3-	36)
37- 40 34 39	(38.9-	39.3) 0.3	(0.3-	0.7) 39	(38.9-	39.3)
Presence of intra-amniotic 
infection/inflammation 
(18-	40	wks)
9 38.1	(22.3-	39.6) 70.6	(6.4-	118.7) 38.1	(22.7-	39.6)
IQR,	interquartile	range.
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These data indicate that T cells and ILCs are the most abundant popula-
tions	in	the	amniotic	fluid	of	women	between	15	and	30	weeks	of	gesta-
tion in the absence of intra- amniotic infection/inflammation.
Next,	 we	 determined	 the	 abundance	 of	 all	 of	 the	 lymphoid	
cell	 populations	 during	 the	 second	 and	 third	 trimester	 (Figure	3).	
Amniotic	fluid	T	cells	were	more	abundant	between	20	and	30	weeks	
of	gestation	than	after	37	weeks	of	gestation	(Figure	3A).	A	flow	cy-
tometry image of an amniotic fluid T cell during the second trimes-
ter	is	shown	in	Figure	3B.	Amniotic	fluid	ILCs	were	most	abundant	
between	 15	 and	 20	weeks	 of	 gestation	 (Figure	3C),	 as	 previously	
reported.119	 Yet,	 their	 number	 reduced	 after	 20	 and	 30	weeks	 of	
gestation	and	remained	low	after	37	weeks	of	gestation	(Figure	3C).	
A	flow	cytometry	image	of	an	amniotic	fluid	ILC	during	the	second	
trimester	 is	shown	 in	Figure	3D.	Amniotic	 fluid	B	cells	did	not	sig-







Together, these data indicate that amniotic fluid T cells and ILCs, fol-
lowed	by	NK	 cells,	 are	most	 abundant	 between	15	 and	30	weeks	
of gestation. These results also show that although B cells are low 
in number such cells are a constant immune cell population in the 
amniotic fluid during the second and third trimester in the absence 
of intra- amniotic infection/inflammation.
3.4 | Immunophenotyping of ILCs and T cells 
in the amniotic fluid in the absence of intra- amniotic 
infection/inflammation
A	previous	study	reported	that	most	of	the	amniotic	fluid	ILCs	be-
long	 to	 the	group	3	 as	 they	express	RORγt and CD161 as well as 
produce high levels of IL- 17 and TNFα.119 It was also shown that 
these	 fetal	 group	 3	 ILCs	 express	 CD103	 (a	 hallmark	 of	 intraepi-
thelial cells) and were present in the amniotic fluid but not in the 
peripheral circulation.119 We, therefore, investigated whether ILCs 
express	RORγt, CD161, and CD103 in the amniotic fluid and periph-
eral	blood	of	healthy	adults	(Figure	4A).	Most	of	the	amniotic	fluid	




of	 CD56+/CD56-	RORγt+	 ILCs	 (Figure	4D,E)	 and	 CD56+/CD56−
CD161+CD103+	ILCs	(Figure	4F,G)	were	higher	in	the	amniotic	fluid	
than in the peripheral circulation.
T cells were abundant in the amniotic fluid of women between 
15	 and	30	weeks	of	 gestation;	 therefore,	we	determined	whether	
such	cells	expressed	the	same	markers	as	ILCs.	Similar	to	amniotic	
fluid	 ILCs,	 a	 high	 proportion	 of	 amniotic	 fluid	 T	 cells	 (Figure	5A)	
expressed	 RORγt	 (Figure	5B).	 The	 proportion	 of	 RORγt+	 T	 cells	























(A) 15-20 wks (B) 20-30 wks (C) 30-36 wks (D) 37-40 wks
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Yet,	the	proportion	of	CD161+CD103+	T	cells	was	higher	in	the	am-
niotic	fluid	than	in	the	peripheral	circulation	(Figure	5E).
Taken	 together,	 these	 results	 indicate	 that	 group	 3	 ILCs	 and	
RORγt+	 T	 cells	 are	 present	 in	 the	 amniotic	 fluid	 between	 15	 and	
30	weeks	 of	 gestation	 in	 the	 absence	 of	 intra-	amniotic	 infection/
inflammation.
3.5 | Myeloid cells in the amniotic fluid during the 
second and third trimester in the absence of intra- 
amniotic infection/inflammation
Next,	 we	 quantified	 the	 number	 of	 myeloid	 cells	 in	 the	 amniotic	
fluid of women during the second and third trimester. The gating 




CD15+	 cells)	 and	 monocytes/macrophages	 (CD45+CD15−CD14+	
cells)	(Figure	6A).	The	number	of	amniotic	fluid	neutrophils	increased	
gradually	from	15	weeks	to	term	gestation	(Figure	6B).	The	number	
of amniotic fluid monocytes/macrophages was greater between 20 
and	 40	weeks	 compared	 to	 15-	20	weeks	 of	 gestation	 (Figure	6C).	
Yet,	the	number	of	these	myeloid	cells	did	not	peak	at	term	pregnancy	
as	occurred	with	amniotic	fluid	neutrophils	(Figure	6B	vs	C).	Lastly,	
neutrophils were more abundant than monocytes/macrophages in 
the	amniotic	fluid	of	women	at	term	(Figure	7A).	A	flow	cytometry	
image of an amniotic fluid neutrophil or monocyte/macrophage dur-
ing the third trimester is shown in Figure 7B or C, respectively. These 
data show the number of amniotic fluid neutrophils increases as ges-
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immune	cell	population	after	20	weeks	of	gestation	in	the	absence	
of intra- amniotic infection/inflammation.
3.6 | Immune cells in the amniotic fluid of women 
with intra- amniotic infection/inflammation
Previous studies have shown that intra- amniotic infection is charac-
terized by the infiltration of neutrophils and monocytes/macropha
ges.23,27,67-69,129-132 It was recently suggested that amniotic fluid ILCs 
were also implicated in regulating intra- amniotic infection and inflam-
mation in preterm gestations.119 Therefore, we evaluated whether am-
niotic fluid immune cells were increased in women with intra- amniotic 
infection/inflammation.	All	of	the	amniotic	fluid	immune	cells,	except	
ILCs, were increased in cases with intra- amniotic infection/inflamma-
tion	(Figure	8A-F).	The	numbers	of	ILCs	in	the	amniotic	fluid	collected	
at	18-	22	weeks	of	gestation	from	women	with	 intra-	amniotic	 infec-
tion/inflammation were similar to those in gestational age- matched 
amniotic fluid samples from women without intra- amniotic infection/
inflammation	(Figure	S1).	The	numbers	of	neutrophils	and	monocytes/
macrophages	were	greater	than	T	cells,	ILCs,	B	cells,	and	NK	cells	in	
the amniotic fluid of women with intra- amniotic infection/inflamma-
tion	(Figure	8E	vs.	A-D&F).	Collectively,	these	data	indicate	that	all	of	
the	amniotic	fluid	immune	cells,	except	ILCs,	participate	in	the	inflam-





























































































































































































8 of 17  |     GOMEZ- LOPEZ Et aL.
4  | DISCUSSION
Principal findings: In the absence of intra- amniotic infection/inflam-







the second and third trimester, yet, they were scarce between 15 
and	20	weeks	of	gestation;	(vi)	amniotic	fluid	NK	cells	were	greater	
between	 15	 and	 30	weeks	 of	 gestation	 than	 at	 term;	 (vii)	 amni-





neutrophils were more abundant than monocytes/macrophages in 
the amniotic fluid of women at term. Lastly, we found that all of 
the	amniotic	fluid	immune	cells,	except	ILCs,	were	increased	in	the	
presence of intra- amniotic infection/inflammation.
4.1 | Amniotic fluid innate lymphoid cells (ILCs)
Recently, it was shown that group 3 ILCs are present in the human 
amniotic	fluid	between	15	and	16	weeks	of	gestation	(second	trimes-
ter).119	Such	innate	lymphocytes	expressed	the	intraepithelial	marker	
CD103, suggesting that they were derived from the fetal intestine.119 
This concept was supported by the fact that group 3 ILCs were found 
in the fetal small intestine and lung, and these cells displayed a simi-
lar phenotype to that detected in the amniotic fluid.119	Herein,	we	ex-
tended these findings by demonstrating that the human amniotic fluid 
contains	group	3	ILCs	(RORγt+CD161+CD103+	ILCs)	during	the	second	
and third trimester; yet, their number is highest earlier in pregnancy.
Previous studies have shown that fetal tissues include different 
subsets	of	ILCs.	In	humans,	both	ILC2-	like	(Lin-	CRTH2+CD127+	cells)	














































































































































































































































































Amniotic fluid innate lymphoid cells (ILCs)
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found	 in	 the	 fetal	 gut	 at	 14-	17	weeks	 of	 gestation.134 In addition, 
group	2	ILCs	(GATA3+	ILCs)	have	been	detected	in	the	umbilical	cord	
blood of term neonates.135 In mice, fetal RORγt+	 ILC	 progenitors	
mature in the fetal liver environment136,137 in a Notch2- dependent 
manner.138	However,	non-	hepatic	 ILC	progenitors	may	exist	 in	 the	
fetal intestine.139	While	group	3	ILCs	exist	in	the	fetal	murine	intes-
tine early in pregnancy, a particular subset that is only a fraction of 
murine	intestinal	ILCs	seems	to	rapidly	expand	shortly	after	birth,140 
which may be related to the colonization of the fetal gut by commen-
sal microbes. Moreover, fetuses with gastroschisis had increased 
group	2	and	group	3	ILCs	in	the	sections	of	intestine	exposed	to	the	
amniotic fluid, suggesting that these cells participate in the inflam-
matory environment that leads to fetal bowel damage.128
Herein, we showed that amniotic fluid ILCs were not significantly in-
creased in women with intra- amniotic infection/inflammation between 
18	and	22	weeks	of	gestation;	yet,	this	finding	needs	to	be	further	in-
vestigated using a larger number of samples. Collectively, these studies 
demonstrate that ILCs, in particular, group 3 ILCs, are an important im-
mune cell subset in both the amniotic cavity and the developing fetus.
4.2 | Amniotic fluid T cells
To	our	knowledge,	we	are	the	first	to	report	that	T	cells	are	an	abun-
dant immune cell population in the amniotic fluid between 15 and 
30	weeks	of	 gestation	 (mostly	 in	 the	 second	 trimester).	 It	 is	 likely	
that these adaptive immune cells are derived from the fetus as 
most	of	the	amniotic	fluid	leukocytes	in	early	gestation	are	of	fetal	
origin.67	 In	addition,	amniotic	 fluid	T-	cells	expressed	high	 levels	of	
RORγt similar to what was observed in amniotic fluid group 3 ILCs 
of fetal origin.119
In humans, T cells are detected in the fetal lymphoid tissues as 
early	 as	 10	weeks	 of	 gestation.141	 By	 12-	14	weeks	 of	 gestation,	 T	
cells are found in the fetal intestine, spleen, and lymph nodes; yet, 
they are more abundant by the end of the second trimester.142	At	
this time, secondary fetal lymphoid tissues contain a high propor-
tion	 of	 CD4+CD25+FoxP3+	 regulatory	 T	 cells	 or	 Tregs143,144 that 
are mostly generated in response to maternal alloantigens.145 Fetal 
Tregs strongly suppress both natural fetal T- cell activity144 and re-
sponses against maternal antigens to prevent maternal- fetal re-
jection.143,144,146 The induction of maternal- specific fetal Tregs is 
orchestrated by transforming growth factor β	(TGF-	β), which is pro-
duced by the fetal lymph nodes.145
Th17 cells have also been identified in the cord blood of term 
neonates;	yet,	their	proportions	are	higher	in	preterm	neonates	ex-
posed to histologic chorioamnionitis.147 Th17 cells are characterized 
by	the	expression	of	RORγt and the production of IL- 17.148 Indeed, 
Tregs	can	promote	a	Th17-	like	phenotype	in	the	context	of	inflam-
mation149	and	Tregs	can	express	RORγt to enhance their suppressive 
F IGURE  5 Amniotic	fluid	T-	cells	
expressing	RORγt, CD161, and CD103. 
A,	Mononuclear	cells	were	isolated	from	
the amniotic fluid of women at 15- 
30	weeks	of	gestation	or	the	peripheral	
blood	(PBMCs)	from	healthy	adults.	
Flow cytometry gating strategy for 
immunophenotyping	of	CD3+	T	cells	
within	the	CD45+CD15−CD14−	gate.	
B, Flow cytometry gating strategy for 
immunophenotyping of RORγt+	T	cells	
within	the	CD45+CD15−CD14−CD3+	
gate. C, Flow cytometry gating 
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F IGURE  7 Neutrophils are the 
dominant myeloid subset in the amniotic 
fluid	at	term.	A,	Number	of	CD15+	
neutrophils	and	CD14+	monocytes/
macrophages in the amniotic fluid from 
women at term. Red lines represent the 
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activity during intestinal inflammation.150 Here, we identified T cells 
in	the	amniotic	fluid	that	express	RORγt, which are greater in cases 
with intra- amniotic infection/inflammation, suggesting that these 
cells	participate	in	the	inflammatory	process	against	MIAC.	Further	
research	is	required	to	investigate	whether	amniotic	fluid	T	cells	are	
indeed of fetal origin and whether these cells have pro- inflammatory 
and/or immunosuppressive functions.
4.3 | Amniotic fluid B cells
The data herein showed that B cells are constantly present during 
the second and third trimester; yet, these cells are very rare be-
tween	15	and	20	weeks	of	gestation.	Previous	observations67,119 
led us to suggest that amniotic fluid B cells may be of fetal origin. 
Fetal pro/pre- B cells can be detected in the omentum as early as 
8	weeks	of	gestation	and	B	cells	can	be	detected	in	the	liver	and	
spleen	at	12	weeks.151	At	this	point,	approximately	40%	of	these	
B	cells	express	CD5,	a	marker	of	fetal	B	cell	 lineage.152,153 By 23 
weeks	of	gestation,	90%	of	fetal	splenic	B	cells	express	CD5	(B1-	
like	cells),	which	gradually	reduce	to	adult	levels	(25%-	35%)	by	late	
adolescence.154	 B-	1	 cells	 (CD5+	 B	 cells)	 are	 responsible	 for	 the	
production of antibodies in response to bacterial cell wall compo-
nents.155 Therefore, these cells limit bacterial colonization before 
the induction of adaptive immune responses.156,157 Indeed, it was 
also suggested that the fetal B cell system could be considered an 
intermediate between the innate immune system and the adap-
tive immune system.158 Here, we provided evidence that amniotic 
fluid B cells are increased in women with intra- amniotic infection/
inflammation, supporting the hypothesis that these adaptive im-
mune	cells	participate	in	the	fetal	host	response	against	MIAC.
4.4 | Amniotic fluid natural killer (NK) cells
In	 this	 study,	 we	 found	 that	 the	 amniotic	 fluid	 includes	 NK	 cells,	
which	 are	most	 abundant	 between	 15	 and	 30	weeks	 of	 gestation	
(mostly	 in	 the	 second	 trimester).	 It	 is	 likely	 that	 amniotic	 fluid	NK	
cells are derived from the fetus as most of the identified immune 





in	utero;	 yet,	 they	 remain	hyporesponsive	 to	HLA	class	 I-	negative	
or allogeneic cells,160 which could be considered a mechanism for 
maternal- fetal tolerance.161,162	 Taken	 together,	 these	 findings	 sug-
gest	that	amniotic	fluid	NK	cells	could	participate	in	the	mechanisms	
of	maternal-	fetal	tolerance	taking	place	in	the	fetal	compartments.	
The	 fact	 that	amniotic	 fluid	NK	cells	are	 increased	 in	women	with	
intra- amniotic infection/inflammation suggests that these cells are 
also	implicated	in	the	fetal	host	response	against	MIAC.
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4.5 | Amniotic fluid neutrophils
Our results showed that amniotic fluid neutrophils increased as ges-
tation progressed, and their number was even greater in women with 
intra-	amniotic	 infection/inflammation.	 Amniotic	 fluid	 neutrophils	
can be of fetal and/or maternal origin.67	Amniotic	 fluid	neutrophils	
are mostly of fetal origin during preterm gestation, whereas these 
cells are of maternal origin at term.67 Regardless of their origin, am-
niotic fluid neutrophils are a part of the innate immune host defense 
mechanisms	 that	 take	 place	 in	 the	 amniotic	 cavity	 of	women	with	




traps	 (NETs),68	 and	 (iii)	 can	phagocytize	microorganisms	 commonly	
found in the lower genital tract, eg, Streptococcus agalactiae	 (also	
known	 as	 group	B	 Streptococcus	 or	GBS),	Ureaplasma urealyticum, 
Gardnerella vaginalis, and Escherichia coli.132 Together, these findings 
show that even in the absence of microbial invasion neutrophils are 




Macrophages have been previously observed in the amniotic fluid 
from	normal	 pregnancies	 using	 cytological	 techniques.110,111,116,117 
Using high-dimensional flow cytometry, we found that mono-
cytes/macrophages are consistently present in the amniotic fluid 
of	women	after	20	weeks	of	gestation.	Monocytes	emerged	during	
the second trimester, suggesting that they have a fetal origin as the 
neutrophils do.67
Fetal macrophages are observed in the early stages of embryonic 
development.169	 Such	 cells	 originate	 in	 the	 yolk	 sac,	 fetal	 liver,	 and	
bone marrow169-171 and can colonize developing organs to become 
tissue residents that persist until adulthood.172 During pregnancy, 
Hofbauer	 cells	 (fetal	 macrophages)	 reside	 in	 the	 placental	 villous	
tree,173-175 indicating that this can be a potential source for amniotic 
fluid macrophages. In cases with intra- amniotic infection/inflamma-
tion,	monocytes/macrophages	are	abundant	and	expressed	high	levels	
of IL- 1α and IL- 1β.69	These	cytokines	participate	in	the	process	of	par-
turition176-178 and host response to intra- amniotic infection.176,178-185
5  | CONCLUSIONS
The amniotic fluid harbors a diverse immune cellular composition 
during	 the	second	and	 third	 trimester.	Between	15	and	20	weeks,	
ILCs are the most abundant in the amniotic fluid. T cells and ILCs, 
followed	by	NK	cells,	are	more	abundant	between	15	and	30	weeks	
than	at	term.	B	cells	are	rare	between	15	and	20	weeks,	but	they	are	
a constant immune cell population until full term. While neutrophils 
increase as gestation progresses, monocytes/macrophages emerged 
after	20	weeks	and	remained	constant	until	term.	All	of	the	amniotic	
fluid	 immune	 cells,	 except	 ILCs,	 are	 increased	 in	 cases	with	 intra-	
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